emat

Buy Complete Report

Prix: €120 HT

Logo CreditCards Visa Logo CreditCards Mastercard

This report is accessible on EMAT, the reference database for private company acquisition multiples

 

 

► Subscribe to EMAT database

 

Sectors covered by our analysts

 

► Studies & indices published by Epsilon Research: Register to receive (free) publications updates

 

► Alert on reports published: Sign up (free) to receive by e-mail updates on EMAT reports published on your preferred sector.

 

Transaction Multiples for the Valuation of Private Companies

Private Group led by Novo A/S / Xellia Group (Xellia Pharmaceuticals)

No EMAT : 62943
Announced Date : 21/05/2013
Type : SBO (Secondary Buy Out) ,Exit
Deal Value : Yes
Acquirer : Private Group led by Novo A/S

Target : Xellia Group (Xellia Pharmaceuticals)
Country : Norway
Sector of activity :
  • Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Pharmaceuticals
  • Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
Xellia Pharmaceuticals AS is a fully integrated specialty pharmaceutical company focusing on the global anti-infective market , with over 100 years of experience and expertise in the supply of...

Transaction multiples available
EV/
Sales
EV/
Gross Profit
EV/
EBITDA
EV/
EBIT
Eq/
PBT
P/E Price
to Book
Specific
multiple(s)
Historic ns
Current
Rating : **
Multiple available
n.s.   Multiple calculated, but not significant

Source: Epsilon Research / EMAT

Comparable Transactions

  • Number of EMAT Reports / sub-sector « Pharmaceuticals » = 129
  • Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 34
Example of comparable transactions on EMAT (same sub-sector):
Date Acquirer Target Country Multiples See details
30/09/2013 Aspen Pharmacare Holdings Fraxiparine and Arixtra brands of GSK and Associated Manufacturing Plant France ** 62935
22/05/2013 Private Group led by Charterhouse Capital Partners LLP DOC Generici Italy *** 62906

Source: Epsilon Research / EMAT

About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

EMAT Report

► Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

 

► Example of EMAT Report